Sarcoma  >>  Ayvakit (avapritinib)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ayvakit (avapritinib) / Blueprint Medicines
NCT03862885: Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

Approved for marketing
N/A
NA
Avapritinib, BLU-285
Blueprint Medicines Corporation
GIST
 
 
NCT05381753: Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

Recruiting
N/A
200
RoW
Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
CStone Pharmaceuticals
Gastrointestinal Stromal Tumors
05/25
10/25
ChiCTR2200062170: A Real-World study of Avapritinib in the treatment of D842V-Mutated gastrointestinal stromal tumors

Not yet recruiting
N/A
104
 
Nil ;Nil
Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Fujian Medical University Scientific Research Development Fund
Gastrointestinal stromal tumor
 
 

Download Options